- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06568692
Een fase 2-onderzoek naar PCS6422 met capecitabine bij patiënten met gevorderde of gemetastaseerde borstkanker
Een fase 2, open-label onderzoek naar PCS6422 met capecitabine bij patiënten met gevorderde of gemetastaseerde borstkanker
This is an adaptive Phase 2, open-label, randomized, multi-center study evaluating up to 2 regimens of PCS6422 with capecitabine (Cap) vs. standard dose of Cap alone in patients with advanced or metastatic breast cancer. The goal of the study is to assess the efficacy and safety of PCS6422 + Cap as a treatment option for patients with advanced or metastatic breast cancer who are not eligible for anthracycline- or taxane-containing therapies, or other available therapies, including PD-1 or PARP inhibitors.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
This is an adaptive Phase 2, open-label, randomized, multi-center study evaluating up to 2 regimens of PCS6422 with Cap vs. standard dose of Cap alone in patients with advanced or metastatic breast cancer who are not eligible for anthracycline- or taxane-containing therapies, or other available therapies, including PD-1 or PARP inhibitors. The goal of the study is to assess the efficacy and safety of PCS6422 + Cap as a treatment option for patients with advanced or metastatic breast cancer who have been treated with chemotherapy in the metastatic setting.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
California
-
Los Angeles, California, Verenigde Staten, 90067
- Valkyrie Clinical Trials
-
Oxnard, California, Verenigde Staten, 93030
- FOMAT Medical Research
-
-
Florida
-
Miami, Florida, Verenigde Staten, 33165
- AP Medical Research
-
Tampa, Florida, Verenigde Staten, 33612
- Moffitt Cancer Center
-
-
Indiana
-
Dyer, Indiana, Verenigde Staten, 46311
- Northwest Cancer Center
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21201
- University of Maryland Medical Center (UMMC)
-
-
New Jersey
-
New Brunswick, New Jersey, Verenigde Staten, 08901
- Rutgers Cancer Institute of New Jersey
-
-
New York
-
Westbury, New York, Verenigde Staten, 11590
- Clinical Research Alliance
-
-
Ohio
-
Canton, Ohio, Verenigde Staten, 44718
- Gabrail Cancer Center Research
-
-
Tennessee
-
Nashville, Tennessee, Verenigde Staten, 37203
- SCRI Oncology Partners
-
-
Texas
-
Austin, Texas, Verenigde Staten, 78731
- Texas Oncology PA (Austin)
-
San Antonio, Texas, Verenigde Staten, 78240
- Texas Oncology PA (San Antonio)
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Aged ≥18 years at Screening
-
Diagnosis of histologically confirmed breast cancer that is unresectable. The following subsets of breast cancer are included:
- Patients with triple-negative breast cancer, advanced or metastatic
- Patients with hormone receptor (HR) positive, ER positive, HER2 negative advanced or metastatic breast cancer
-
Has measurable disease in accordance with RECIST 1.1 obtained by imaging within 28 days prior to C1D1
-
Other therapies are not indicated (eg, resistant or intolerant to taxanes and/or an anthracycline-containing regimen) for treatment of advanced or metastatic breast cancer
-
Has a life expectance of at least 24 weeks
-
Has Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1 at screening
-
Has adequate bone marrow, liver, and renal function as assessed by the following laboratory requirements conducted within 7 days before C1D1 (Note: labs will also be repeated pre-dose on C1D1 to confirm eligibility): a. Hemoglobin ≥9 g/dL (≥90 g/L) b. Adequate renal function by estimated glomerular filtration rate (eGFR) defined as a creatinine clearance >50 mL/min (>0.84 mL/s) (Cockcroft-Gault equation) and normalized to body surface area c. Peripheral absolute neutrophil count (ANC) of ≥1.5×109/L d. Platelet count of ≥100×109/L without growth factor/transfusion e. Total bilirubin <1.5× upper limit of normal (ULN); or ≤3×ULN if the patient has Gilbert's disease f. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) <2.5×ULN, with liver metastasis <5×ULN g. International normalized ratio (INR) <1.5 and prothrombin time (PT) ≤1.5×ULN, unless both of the following conditions are met: i. Patient is receiving anticoagulant therapy, and ii. PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulant h. Activated partial thromboplastin time (aPTT) ≤1.5×ULN, unless both of the following conditions are met: i. Patient is receiving anticoagulant therapy, and ii. PT or PTT is within therapeutic range of intended use of anticoagulants
Exclusion Criteria:
-
Received any line of treatment for advanced or metastatic breast cancer within 21 days or 5 half-lives (whichever is longer) prior to randomization
-
Currently receiving any hormone replacement therapy, unless discontinued within 21 days prior to randomization
-
Received IV 5-FU or oral 5-FU analog in the 4 weeks prior to C1D1
-
Received DPD inhibitor within 4 weeks prior to C1D1
-
Has homozygous or compound heterozygous DPYD variants that result in complete or near-complete absence of DPD activity
-
Cardiac:
-
Has history or presence of clinically significant abnormal 12-lead electrocardiogram (ECG) results, in the Medical Monitor or Investigator's opinion
-
Has prolonged QTc (with Fridericia's correction) of >480 msec performed at Screening
-
Has a history of prolonged QTc interval, ventricular tachycardia/fibrillation or significant ventricular arrhythmia, or Torsades de Pointes, or a history of ventricular ablation for arrhythmia
-
Has congenital long QT syndrome or a family history of long QT syndrome
-
Has other clinically significant cardiac disease including, but not limited to, myocardial infarction, unstable angina, cardiac or other vascular stenting, angioplasty, or surgery ≤12 months prior to randomization, congestive heart failure
- Class II per the New York Heart Association, or history of myocarditis
-
-
Is pregnant or breastfeeding
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: PCS6422 40 mg + Capecitabine 300 mg
Fixed single dose of PCS6422 administered with Capecitabine 150 mg BID over 7 days |
PCS6422 is an experimental drug that, when combined with capecitabine, may make the immune response more active against cancer.
Andere namen:
|
|
Experimenteel: PCS6422 40 mg + Capecitabine 450 mg or 150 mg
Fixed single dose of PCS6422 administered with Capecitabine 225 mg or 75 mg BID over 7 days |
PCS6422 is an experimental drug that, when combined with capecitabine, may make the immune response more active against cancer.
Andere namen:
|
|
Actieve vergelijker: Capecitabine 2000 mg/m2
Standard capecitabine dose at 1000 mg/m2 BID |
Commercially available capecitabine is a commonly used oral fluoropyrimidine.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Evaluation of Objective Response Rate (ORR)
Tijdsspanne: Up to 24 weeks post End of Treatment (EoT)
|
The proportion of patients who achieved a confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) |
Up to 24 weeks post End of Treatment (EoT)
|
|
Number of patients with adverse events (AEs)
Tijdsspanne: During treatment, an average of 8 months
|
Frequency, duration, and severity of AEs across treatment groups |
During treatment, an average of 8 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Evaluation of Disease Control Rate (DCR)
Tijdsspanne: Up to 24 weeks post End of Treatment (EoT)
|
The proportion of patients with objective evidence of CR or PR or stable disease (SD) according to RECIST 1.1 |
Up to 24 weeks post End of Treatment (EoT)
|
|
Evaluation of Duration of Response (DOR)
Tijdsspanne: Up to 24 weeks post End of Treatment (EoT)
|
The proportion of patients with DOR |
Up to 24 weeks post End of Treatment (EoT)
|
|
Evaluation of Time to Response (TTR)
Tijdsspanne: Every 12 weeks during treatment
|
The number of patients with days to response |
Every 12 weeks during treatment
|
|
Evaluation of Progression Free Survival (PFS)
Tijdsspanne: Up to 24 weeks post End of Treatment (EoT)
|
Patients with number of days of progression free response |
Up to 24 weeks post End of Treatment (EoT)
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Mridula George, MD, Rutgers University
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per site
- Neoplasmata
- Huidziektes
- Borst ziekten
- Huid- en bindweefselaandoeningen
- Borstneoplasmata
- Drievoudige negatieve borstneoplasmata
- Heterocyclische verbindingen, 1-ring
- Heterocyclische verbindingen
- Nucleïnezuren, nucleotiden en nucleosiden
- Deoxycytidine
- Cytidine
- Pyrimidine -nucleosiden
- Pyrimidines
- Nucleosiden
- Uracil
- Pyrimidinonen
- Deoxyribonucleosides
- Fluorouracil
- Capecitabine
- eniluracil
Andere studie-ID-nummers
- PCS6422-BC-01
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .